After a discounted first month of $45, the ongoing membership is $145 and covers provider check-ins, progress tracking, messaging access, and support services like an insurance concierge
Some states (e.g., Washington, Oregon, South Carolina) still allow coverage for obesity treatment but impose strict prior authorization, indication limits and step therapy
Overview of main clinical studies for MASLD/MASH with GLP-1 receptor agonists and dual or triple agonists targeting glucagon/GIP/GLP-1 receptors Liraglutide Liraglutide, a once-daily GLP-1 receptor agonist with authorized indications for type 2 diabetes and obesity, was evaluated in the LEAN trial (NCT01237119), a phase 2 randomized controlled study enrolling 52 adults with biopsy-proven MASH [22]
Extending the half-life also extends the pharmacokinetic properties of liraglutide - upregulating intracellular cAMP levels via GPCR-signaling pathway in elevated blood glucose concentrations, promoting insulin release, and attenuating glucagon secretion